SOX in the Boardroom: What the Sarbanes?Oxley Act Means to You

Publication
Article
BioPharm InternationalBioPharm International-06-01-2003
Volume 16
Issue 6

by Penny Cass, BioPharm International Stay current on the changes in corporate governance regulations ? whether your company is public or private, in the United States or elsewhere. As a capital-intensive industry, many of our third-party associations are going to require that biopharmaceutical companies comply with the new regulations to receive financing. The trend to regulate corporate governance activities hasn't ended ? more rules promulgated by more government entities should be anticipated.

Newsletter

Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.

Recent Videos
Daniel Fischer, Tevard
Junevity Co-founder & CEO, John Hoekman, PhD
DC skyline at night with view of the White House and the Washington Monument | Image Credit: © Jessica - stock.adobe.com
Daniel Fischer, Tevard
Related Content
© 2025 MJH Life Sciences

All rights reserved.